Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Crinetics Pharmaceuticals, Inc. EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner June 18, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly June 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs May 30, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts May 22, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024 May 08, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 May 02, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients March 19, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome March 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 11, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update February 28, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement February 28, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 February 14, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 12, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 10, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome December 18, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 11, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences November 20, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 07, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023 September 20, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock September 12, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock September 11, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly September 10, 2023 From Crinetics Pharmaceuticals, Inc. Via GlobeNewswire Tickers CRNX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.